VLPbio is a pioneer biotechnology company focused on research and development of Chimeric Virus like Particles (VLPs) as vaccines for human health.
Development of innovative vaccines for the world's major pharmaceutical markets, based on the platform protected and proprietary VLP (virus like particles).
VLPbio owns a leading technology platform based in Virus Like Particles (Q-VLP) allowing to develop a large variety of innovative drugs
VLPbio is developing a strong product portfolio of vaccines, where Cervivax, a therapeutic vaccine against cervical cancer is our most advance candidate.
The achievements of stimulating the immune system through vaccination have been profound, saving millions from sickness and death. VLPbio is advancing breakthroughs to extend this legacy to many of today’s challenging diseases. Our vaccines are designed to treat as well as prevent illness, aiming to break the body’s tolerance of cancerous cells and protect against diverse, changing strains of infectious diseases.